24 completed, 8 recruiting, 6 unknown, 4 terminated. 17 Phase 2, 9 Phase 1, 8 Phase 3, 7 Not applicable, 1 Early Phase 1.
Follow GVHD: new trials by email Literature Review of GVHD trials Research Report on GVHD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vorinostat for Graft-versus-host Disease (GVHD) Prevention in Non-Malignant Adolescent and Young Adults (AYA) Population Vorinostat - GVHD | Phase 2 | Recruiting | Sung Won Choi | 55 | 2026-12-01 | 2026-10-16 |
| Effects of Axatilimab on Skin in Chronic Graft-versus-Host Disease Axatilimab - Chronic Graft vs. Host Disease, GVHD | Not yet recruiting | Northwestern University | 15 | 2026-11-01 | 2026-09-22 | |
| Quantification of Peripheral Blood iNKTs After Allogeneic Stem Cell Transplantation blood draw - Allogeneic HSCT, Posttransplant Complications | Recruiting | University Hospital Pilsen | 75 | 2026-08-01 | 2026-08-13 | |
| TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT Tacrolimus, Early Tacrolimus Taper Strategy - GVHD, Hematopoietic Cell Transplantation (HCT) | Phase 1 | Recruiting | Stanford University | 50 | 2026-07-21 | 2026-08-17 |
| Diagnostic Refinement and Educational Approaches in Managing Bone Marrow Transplantation App-based Educational Intervention - GVHD, Bone Marrow Transplant Complications | Not applicable | Recruiting | Scripps Health | 60 | 2026-04-02 | 2026-04-09 |
| Autologous Serum Obtained by a Closed-Circuit Collection Device Autologous Serum 20% - GVHD, Meibomian Gland Dysfunction (Disorder) | Phase 2 | Active not recruiting | GIANCARLO FATOBENE | 16 | 2025-06-20 | 2026-10-21 |
| Psychiatric Status and Symptom Severity in Graft-versus-Host Disease (GvHD). GVHD, Chronic, GVHD - Graft-Versus-Host Disease | Recruiting | Medical University of Gdansk | 200 | 2025-04-08 | 2026-01-02 | |
| Safety and Efficacy of Treg Cell in the Treatment of GVHD Regulator T Cells - GVHD | Phase 1 / Phase 2 | Not yet recruiting | Xuzhou Medical University | 20 | 2024-06-01 | 2024-05-13 |
| Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT) TRX103 - Hematologic Malignancy, GvHD | Phase 1 | Recruiting | Tr1X, Inc. | 36 | 2024-04-08 | 2025-04-15 |
| Prophylaxis of Graft-versus-host Disease With Anti-CD25 Antibody in Patients Underwent HSCT CD25 treatment, low-dose ATG - GVHD | Phase 2 | Unknown | Wang Xin | 40 | 2024-03-26 | 2024-03-28 |
| Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor Grafalon, Thymoglobulin - GVHD | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 324 | 2023-11-28 | 2026-04-27 |
| In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases Blood sample taken at a single time point - Autoimmune Diseases, Inflammatory Disease | Not applicable | Completed | Assistance Publique - Hôpitaux de Paris | 67 | 2023-10-02 | 2026-02-11 |
| Comparison of Different Dose of Post-transplantation Cyclophosphamide as Graft Versus Host Disease Prophylaxis PTCY - GVHD | Phase 3 | Unknown | Shanghai Jiao Tong University School of Medicine | 138 | 2023-10-01 | 2023-08-21 |
| MAP-guided Preemptive Therapy of aGvHD by Ruxolitinib Ruxolitinib - GVHD, Acute Stem Cell Transplant Complications | Phase 2 | Unknown | Sichuan University | 62 | 2023-10-01 | 2023-10-10 |
| Effect of PMSCs and Their Secretome for the Treatment of GvHD Secretome (set of substances released from the cell to its surroundings) of mesenchymal stem cells retrieved from the placenta (containing 400 microgram protein/ milliliter), 4 cc distilled water dissolved in albumin 20% - GVHD | Phase 3 | Completed | Tabriz University of Medical Sciences | 60 | 2023-01-01 | 2024-06-21 |
| A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant Photobiomodulation Therapy, Placebo sham device - Graft-Versus-Host Disease, GVHD | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 44 | 2022-12-22 | 2026-05-22 |
| Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD) Apraglutide - GVHD | Phase 2 | Terminated | VectivBio AG | 31 | 2022-05-25 | 2025-10-20 |
| A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR) Itolizumab, EQ001 Placebo - Graft Versus Host Disease, GVHD | Phase 3 | Terminated | Equillium | 158 | 2022-04-29 | 2025-06-17 |
| Fecal Microbiota Transplant (FMT) Capsule for Improving the Efficacy of GI-aGVHD FMT - GVHD | Early Phase 1 | Unknown | Shenzhen Xbiome Biotech Co., Ltd. | 15 | 2021-11-01 | 2021-10-26 |
| Outcomes of Patients After Allo-HSCT With Decitabine and NAC decitabine, Acetylcysteine, Semustine - Engraft Failure, Relapse | Phase 3 | Unknown | The First Affiliated Hospital of Soochow University | 100 | 2021-07-01 | 2021-06-30 |
Showing 20 of 46. Sign in to see all of them.
Graft vs Host Disease (23) · Myelodysplastic Syndromes (5) · Leukemia, Myeloid, Acute (4) · Leukemia, Myelomonocytic, Chronic (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Bronchiolitis Obliterans Syndrome (2) · Dry Eye Syndromes (2) · Hematologic Neoplasms (2) · Recurrence (2) · Alopecia (1) · Anemia, Refractory, with Excess of Blasts (1) · Arthritis, Rheumatoid (1) · Autoimmune Diseases (1) · Cognitive Dysfunction (1) · Cytomegalovirus Infections (1)
Immune System Diseases (23) · Hemic and Lymphatic Diseases (8) · Hematologic Diseases (7) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Bone Marrow Diseases (5) · Disease Attributes (5) · Leukemia (5) · Leukemia, Myeloid (5) · Immunoproliferative Disorders (4) · Lymphatic Diseases (4) · Lymphoproliferative Disorders (4) · Chronic Disease (3)
Tacrolimus (6) · Sirolimus (5) · Cyclophosphamide (4) · Blood Specimen Collection (2) · Busulfan (2) · Mycophenolic Acid (2) · fludarabine (2) · itolizumab (2) · thymoglobulin (2) · 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (1) · Abatacept (1) · Acetylcysteine (1) · Antilymphocyte Serum (1) · Bortezomib (1) · Brentuximab Vedotin (1)
H. Lee Moffitt Cancer Center and Research Institute (3) · Assistance Publique - Hôpitaux de Paris (2) · Fondazione IRCCS Policlinico San Matteo di Pavia (2) · John Levine (2) · Biocon Limited (1) · Dana-Farber Cancer Institute (1) · Dimitrios Tzachanis, MD PhD (1) · Equillium (1) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (1) · GIANCARLO FATOBENE (1) · Hackensack Meridian Health (1) · Henry Ford Health System (1) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (1) · Lophius Biosciences GmbH (1) · Massachusetts General Hospital (1)
United States (25) · China (4) · Italy (4) · France (3) · Germany (3) · Australia (2) · Israel (2) · Portugal (2) · South Korea (2) · Spain (2) · Belgium (1) · Brazil (1) · Canada (1) · Czechia (1) · Iran (1)
Agnieszka Piekarska, MD PhD (1) · Ahmad Al-Homsi, MD (1) · Alexander Misharin, MD, PhD (1) · Alina Markova, MD (1) · Anne Kuan (1) · Babak Nejati, MD (1) · Daniel Wolff, Prof. Dr. med. (1) · Dimitrios Tzachanis, MD PhD (1) · Divya Koura, MD (1) · Eli Lewis, Professor (1) · Farhad Khimani, M.D. (1) · Graciela Pavon-Djavid, PhD (1) · Hossein Ghasemi Moghadam, MD (1) · Jake New, MD, PhD (1)
PMID 19539216, PMID 28473406, PMID 29382747, PMID 31879324, PMID 33351103, PMID 33753457, PMID 34242388, PMID 35484649, PMID 36095841, PMID 37189240, PMID 37341189, PMID 40554429, PMID 40859356, PMID 42495646
P01CA039542 (1), R01HL133823 (1)